TVM Capital Life Science

TVM Capital Life Science is a leading international venture capital firm specializing in life sciences innovation. With approximately $900 million under management and offices in Munich and Montreal, it focuses on investing in therapeutics and medical technologies from North America and Europe that represent first-in-class or best-in-class assets with potential to transform standard of care. The firm's dual investment strategy includes creating single asset/project-focused companies for early-stage therapeutics—often leveraging a strategic partnership with Eli Lilly—and investing directly into commercial-stage medtech/diagnostics/digital health as well as late-stage therapeutics. Its focus areas include oncology, immunology, diabetes/metabolic disorders, CNS/neurodegeneration/pain/cardiovascular diseases/rare diseases. Notable recent investments include Smart Reporting and Anciata Therapeutics[1][3][6].